Innoviva Specialty Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Innoviva Specialty Therapeutics's estimated annual revenue is currently $17.2M per year.
- Innoviva Specialty Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Innoviva Specialty Therapeutics has 111 Employees.
- Innoviva Specialty Therapeutics grew their employee count by 152% last year.
Innoviva Specialty Therapeutics's People
Name | Title | Email/Phone |
---|
Innoviva Specialty Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Innoviva Specialty Therapeutics?
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious disease. Our approved treatments are indicated for use in life-threatening circumstances for seriously ill patients, and our investigational therapies are in development for patients fighting drug-resistant pathogens.\n\nGrowing antimicrobial resistance to existing therapies represents an urgent threat to global public health, and is directly related to significant mortality rates and longer, more expensive hospital stays. We are proud to work with physicians, nurses, hospital pharmacists and administrators, and all who devote their time to caring for patients.
keywords:N/AN/A
Total Funding
111
Number of Employees
$17.2M
Revenue (est)
152%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $38.7M | 112 | 12% | $511.5M |
#2 | $11.4M | 114 | 15% | N/A |
#3 | $11.4M | 114 | 1% | N/A |
#4 | $17.8M | 115 | 5% | $112.1M |
#5 | $29.4M | 117 | -28% | N/A |